Introduction
Amanta Healthcare Limited, a leading player in the pharmaceutical sector, is taking significant steps to enhance its operations and market presence by filing a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company plans to raise substantial funds through an Initial Public Offering (IPO), aiming to further its development in the specialized sector of sterile liquid products.
IPO Details
The IPO will comprise up to 1,25,00,000 equity shares, with a face value of ₹10 each, issued entirely as a fresh issue. This fundraising effort is crucial for Amanta as it seeks to bolster its financial position and expand its manufacturing capabilities.
Funding Objectives
Capital Expenditure Requirements
Amanta Healthcare’s primary objective for raising funds through the IPO includes:
- Financing civil construction work, enhancing infrastructure for future growth.
- Purchasing state-of-the-art equipment, plant, and machinery to establish a new manufacturing line for SteriPort located in Hariyala, Kheda, Gujarat.
- Investing in a new Small Volume Parenteral (SVP) manufacturing line at the same facility.
- Addressing general corporate needs to ensure smooth operational activities and support strategic initiatives.
About Amanta Healthcare
Amanta Healthcare is renowned for its expertise in developing, manufacturing, and marketing sterile liquid pharmaceuticals. The company employs advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) to produce high-quality parenteral solutions that allow for rapid drug absorption, catering to patients who may be unable to take medications orally.
Product Range and Manufacturing Capabilities
The company specializes in manufacturing both large and small volume parenterals (LVPs and SVPs) across six therapeutic segments, including fluid therapy, ophthalmics, respiratory care, and medical devices. Their manufacturing facility in Gujarat adheres strictly to global Good Manufacturing Practices (GMP) standards. Amanta Healthcare exports its products to 19 countries and boasts 113 active international product registrations, signaling its robust global presence.
Market Operations in India
In the Indian market, Amanta Healthcare markets over 45 generic products through a well-established network of 289 distributors. The company also collaborates with other pharmaceutical firms to manufacture products at scale, showcasing its operational versatility and commitment to quality healthcare service delivery.
Management and Innovation
Led by a highly experienced management team, Amanta Healthcare places significant emphasis on innovation and quality assurance. The drive for continuous improvement and adherence to the highest healthcare standards positions the company favorably in a competitive market, making it a promising investment opportunity as it embarks on this IPO journey.
Industry Context
Beyond Amanta Healthcare, it’s noteworthy that other companies such as All Time Plastics, Scoda Tubes, and Dev Accelerator (DevX) have also filed their DRHPs with SEBI, indicating a surge in IPO activity within the market. This trend illustrates the growing confidence of companies looking to access capital markets to fund their expansion and development initiatives.
